InsiderClue
Stocks · Health care · Pharmaceutical Preparations

LIGAND PHARMACEUTICALS INC

LGND Clue Score50
United States Fiscal year ends December CIK 0000886163 Results filed 29 Oct 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

8
Insider
Date
Role
Action
Shares
Price
Amount
Octavio Espinoza
9 May 2025
Chief Financial Officer
Buy
500
$104.40
$52.20K
Octavio Espinoza
9 May 2025
Chief Financial Officer
Buy
1,000
$103.89
$103.89K
Todd C Davis
9 May 2025
Chief Executive Officer
Buy
5,523
$105.67
$583.63K
Todd C Davis
9 May 2025
Chief Executive Officer
Buy
2,307
$104.53
$241.15K
Todd C Davis
9 May 2025
Chief Executive Officer
Buy
1,680
$104.57
$175.68K
Todd C Davis
8 Aug 2024
Chief Executive Officer
Buy
2,500
$97.39
$243.48K
Todd C Davis
22 Sep 2023
Chief Executive Officer
Buy
4,000
$59.38
$237.53K
Matthew W Foehr
13 May 2022
President and COO
Buy
2,500
$82.76
$206.91K
Showing 250 of 377 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 418
Amendments (4/A) skipped 11
Filings about a different issuer 6
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 51
Sales straight out of an exercise 149
Sales at will 85
Transactions with no price 0
Shares from compensation/vesting 2,217,470
Sales filed before the plan box existed 45
History held since 29 Sep 2006